{
  "source": "PA-Med-Nec-Mulpleta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2344-1\nProgram Prior Authorization/Medical Necessity\nMedication Mulpleta® (lusutrombopag)\nP&T Approval Date 7/2024\nEffective Date 1/1/2025\n1. Background:\nMulpleta (lusutrombopag) is a thrombopoietin receptor agonist indicated for the treatment of\nthrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a\nprocedure.\n2. Coverage Criteriaa:\nA. Thrombocytopenia\n1. Mulpleta will be approved based on all of the following criteria:\na. Diagnosis of thrombocytopenia\n-AND-\nb. Patient has chronic liver disease\n-AND-\nc. Patient is scheduled to undergo a procedure\n-AND-\nd. History of failure, contraindication, or intolerance to Doptelet (avatrombopag)\nAuthorization will be issued for 1 month.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Mulpleta [Package Insert]. Florham Park, NJ: Shionogi, Inc.; April 2020.\nProgram Prior Authorization/Medical Necessity – Mulpleta (lusutrombopag)\nChange Control\n7/2024 New program.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}